Where next in clinical asthma research? An innovative approach to research prioritisation by Hallsworth, M, Major, P, Barnes, N

Medical management of parapneumonic pleural disease. by Barnes, N, Hull, J, Thomson, A

Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis by Pavord, I, Lettis, S, Anzueto, A, Barnes, N

Assessment of the acceptability of a new salbutamol multidose dry powder inhaler (DPI) in patients with asthma by Morice, A, Stradling, JR, Barnes, N, Grp, C

The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised by Pascoe, S, Pavord, I, Hinds, D, Locantore, N, Barnes, N

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids by Siddiqui, S, Pavord, I, Barnes, N, Guasconi, A, Lettis, S, Pascoe, S, Petruzzelli, S

Efficacy and safety of a novel beclomethasone dipropionate dry powder inhaler (Clickhaler) for the treatment of adult asthma. Amsterdam Clinical Study Group. by Stradling, JR, Pearson, MG, Morice, A, Peake, MD, Barnes, N

Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. by Macfarlane, A, Dworski, R, Sheller, JR, Pavord, I, Kay, AB, Barnes, N

Efficacy and safety of a novel beclomethasone dipropionate dry powder inhaler (Clickhaler (R)) for the treatment of adult asthma by Stradling, JR, Pearson, MG, Morice, A, Peake, MD, Barnes, N, Grp, A

Blood eosinophil levels as a biomarker in COPD by Brusselle, G, Pavord, I, Landis, S, Pascoe, S, Lettis, S, Morjaria, N, Barnes, N, Hilton, E

Increases in eotaxin-positive cells in induced sputum from atopic asthmatic subjects after inhalational allergen challenge. by Zeibecoglou, K, Macfarlane, A, Ying, S, Meng, Q, Pavord, I, Barnes, N, Robinson, D, Kay, AB

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. by Pavord, I, Jeffery, P, Qiu, Y, Zhu, J, Parker, D, Carlsheimer, A, Naya, I, Barnes, N

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol by Pascoe, S, Lipson, D, Locantore, N, Barnacle, H, Brealey, N, Mohindra, R, Dransfield, M, Pavord, I, Barnes, N

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. by Barnes, N, Qiu, Y, Pavord, I, Parker, D, Davis, P, Zhu, J, Johnson, M, Thomson, N, Jeffery, P

Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control. by Barnes, N, Laviolette, M, Allen, D, Flood-Page, P, Hargreave, F, Corris, P, O'Connor, B, Tate, H, Parker, D, Pavord, I

Variation in the provision and practice of implant-based breast reconstruction in the UK: Results from the iBRA national practice questionnaire by Mylvaganam, S, Conroy, E, Williamson, P, Barnes, N, Cutress, R, Gardiner, M, Jain, A, Skillman, J, Thrush, S, Whisker, L, Blazeby, J, Potter, S, Holcombe, C

Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. by Gamble, E, Qiu, Y, Wang, D, Zhu, J, Vignola, A, Kroegel, C, Morell, F, Hansel, T, Pavord, I, Rabe, K, Barnes, N, Jeffery, P

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. by Barnes, N, Pavord, I, Chuchalin, A, Bell, J, Hunter, M, Lewis, T, Parker, D, Payton, M, Collins, L, Pettipher, R, Steiner, J, Perkins, C

Adherence to best practice consensus guidelines for implant-based breast reconstruction: Results from the iBRA national practice questionnaire survey by Mylvaganam, S, Conroy, E, Williamson, P, Barnes, N, Cutress, R, Gardiner, M, Jain, A, Skillman, J, Thrush, S, Whisker, L, Blazeby, J, Potter, S, Holcombe, C

Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? by Vanfleteren, L, Kocks, J, Stone, I, Breyer-Kohansal, R, Greulich, T, Lacedonia, D, Buhl, R, Fabbri, L, Pavord, I, Barnes, N, Wouters, E, Agusti, A